ePrints@IIScePrints@IISc Home | About | Browse | Latest Additions | Advanced Search | Contact | Help

Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2

Sajna, KV and Kamat, S (2020) Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. In: Cytotherapy .

cry_2020.pdf - Published Version

Download (923kB) | Preview
Official URL: https://dx.doi.org/10.1016/j.jcyt.2020.08.009


In view of devastating effects of COVID-19 on human life, there is an urgent need for the licened vaccines or therapeutics for the SARS-CoV-2 infection. Age-old passive immunization with protective antibodies to neutralize the virus is one of the strategies for emergency prophylaxis and therapy for coronavirus disease 2019 (COVID-19). In this review, the authors discuss up-to-date advances in immune-based therapy for COVID-19. The use of convalescent plasma therapy as the first line of defense to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been established, with encouraging results. Monoclonal antibodies (mAbs) that bind to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein or block the interaction between SARS-CoV-2 RBD and the human angiotensin-converting enzyme 2 receptor have been found to be very promising as a countermeasure for tackling the SARS-CoV-2 infection, and clinical trials are underway. Considering the counterproductive antibody-dependent enhancement of the virus, mAbs therapy that is safe and efficacious, even in people with underlying conditions, will be a significant breakthrough. In addition, emerging immunotherapeutic interventions using nanobodies and cellular immunotherapy are promising avenues for tackling the COVID-19 pandemic. The authors also discuss the implication of mAbs as mediators of cytokine storm syndrome to modify the immune response of COVID-19 patients, thus reducing the fatality rate of COVID-19 infection. © 2020 International Society for Cell & Gene Therapy

Item Type: Journal Article
Publication: Cytotherapy
Publisher: Elsevier B.V.
Additional Information: The copyright of this article belongs to Elsevier B.V.
Department/Centre: Division of Biological Sciences > Biochemistry
Date Deposited: 01 Dec 2020 10:45
Last Modified: 01 Dec 2020 10:45
URI: http://eprints.iisc.ac.in/id/eprint/67130

Actions (login required)

View Item View Item